EMG
LCTX icon

ETF Managers Group’s Lineage Cell Therapeutics LCTX Stock Holding History

ETF Managers Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$478K Sell
318,596
-35,395
-10% -$49.4K 0.02% 459
2022
Q4 		$414K Buy
353,991
+24,165
+7% +$30.5K 0.02% 395
2022
Q3 		$373K Buy
329,826
+24,892
+8% +$36.6K 0.01% 525
2022
Q2 		$491K Buy
304,934
+112,307
+58% +$148K 0.01% 497
2022
Q1 		$289K Sell
192,627
-15,108
-7% -$23.4K 0.01% 544
2021
Q4 		$519K Buy
+207,735
New +$486K 0.01% 515

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $1.07B AUM 75.73% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return